1. 135PMulti-gene panel testing at the hereditary breast and ovarian cancer (HBOC) unit of the Hospital Clinic of Barcelona. (13th May 2019) Authors: Adamo, B; Moreno, L; Gaba, L; Vidal, M; Pascual, T; Chic, N; Alonso, I; Puig-Butillé, J A; Muñoz, M; Prat, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 190PDResearch-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. (23rd October 2018) Authors: Bianchini, G; Parker, J; Carey, L; Perou, C M; Sica, L; Prat, A; Pieńkowski, T; Im, Y-H; Bianchi, G V; Ling-Ming, T; Liu, M-C; Lluch, A; Semiglazov, V; de la Haba-Rodriguez, J; Oh, D-Y; Poirier, B; Pedrini, J L; Valagussa, P; Gianni, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 199PAnti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study. (23rd October 2018) Authors: Prat, A; Adamo, B; Perez Fidalgo, J A; Blanch, S; Martinez, N; Gomez Pardo, P; López González, A; Murillo Juso, L; Amillano, K; Vidal, M; Pascual, T; Pare, L; Canes, J; Galvan, P; Gonzalez Farre, B; Ortega Cebrian, V; Gonzalez, X; Bellet Ezquerra, M; Villagrasa, P; Ciruelos, E M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 20PERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC). (13th May 2019) Authors: Griguolo, G; Brasó-Maristany, F; Pascual, T; Chic, N; Vidal, M; Adamo, B; Giarratano, T; Dieci, M V; Guarneri, V; Prat, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 284OPrimary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study). (23rd October 2018) Authors: Pernas, S; Villagrasa, P; Vivancos, A; Scaltriti, M; Rodon, J; Burgues, O; Nuciforo, P G; Canes, J; Dueñas, M; Vidal, M; Lluch, A; Perelló, A; Llombart, A; Dorca, J; Montaño, Á; Oliveira, M; Ribas, G; Rapado, I; Prat, A; Ciruelos, E M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 369TiPPATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (23rd October 2018) Authors: Loibl, S; Metzger, O; Mandrekar, S J; Mundhenke, C; Seiler, S; Valagussa, P; DeMichele, A; Lim, E; Tripathy, D; Winer, E P; Huang, C; Carey, L; Francis, P; Miller, K D; Goetz, M P; Prat, A; Loi, S; Krop, I; Gianni, L; Ciruelos, E M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 7OPAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer. (13th May 2019) Authors: Prat, A; Tsai, Y-H; Pascual, T; Paré, L; Vidal, M; Adamo, B; Brase, J C; Johnston, S R D; Ciruelos, E M; Parker, J S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 84TiPHER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib. (13th May 2019) Authors: Tomasevic, Z; Smyth, L M; Saura, C; Boni, V; Garcia-Sáenz, J Á; Prat, A; Eli, L; Garza, S J; Lalani, A S; Crown, J P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (23rd March 2019) Authors: Veeraraghavan, J; Angelis, C De; Mao, R; Wang, T; Herrera, S; Pavlick, A C; Contreras, A; Nuciforo, P; Mayer, I A; Forero, A; Nanda, R; Goetz, M P; Chang, J C; Wolff, A C; Krop, I E; Fuqua, S A W; Prat, A; Hilsenbeck, S G; Weigelt, B; Reis-Filho, J S Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. (12th October 2017) Authors: Nuciforo, P; Pascual, T; Cortés, J; Llombart-Cussac, A; Fasani, R; Paré, L; Oliveira, M; Galvan, P; Martínez, N; Bermejo, B; Vidal, M; Pernas, S; López, R; Muñoz, M; Garau, I; Manso, L; Alarcón, J; Martínez, E; Rodrik-Outmezguine, V; Brase, J C Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗